Image
A Multimedia Activity

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Suggested Readings

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, et al. Pharmacol Res. 2013;76:1-8.

Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies.

Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.

The future of Janus kinase inhibitors in inflammatory bowel disease.

De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.

JAK inhibition in inflammatory bowel disease.

Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.

Tofacitinib as induction and maintenance therapy for ulcerative colitis.

Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Vermeire S, et al. Lancet. 2017;389(10066):266-275.

Activity
The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Hepatitis C is Curable

Got it? Treat it!

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

IBD Journal Club:

Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD

Cause for Alarm

New Avenues to the Management of Severe Asthma

Maybe It’s NOT Mechanical Back Pain

Getting on the Fast Track to Identify AxSpA

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Choosing Your Path in Systemic Lupus Erythematosus

From Patient Evaluations to New Targeted Therapies

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

Anemia in Chronic Kidney Disease

New Avenues to Improve Patient Outcomes

What’s Next

Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis

New Horizons in Severe Asthma

From the Airway Epithelium to Improved Patient Outcomes

Making the Rounds on Systemic Mastocytosis

Accelerating Diagnosis and Treatment